{"id":"NCT03059992","sponsor":"Scynexis, Inc.","briefTitle":"Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment","officialTitle":"Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-01","primaryCompletion":"2023-08-25","completion":"2023-08-25","firstPosted":"2017-02-23","resultsPosted":"2024-11-20","lastUpdate":"2024-11-20"},"enrollment":233,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Invasive Candidiasis","Mucocutaneous Candidiasis","Coccidioidomycosis","Histoplasmosis","Blastomycosis","Chronic Pulmonary Aspergillosis","Allergic Bronchopulmonary Aspergillosis","Invasive Pulmonary Aspergillosis","Recurrent Vulvovaginal Candidiasis","Other Emerging Fungi"],"interventions":[{"type":"DRUG","name":"Ibrexafungerp","otherNames":["SCY-078"]}],"arms":[{"label":"Ibrexafungerp (SCY-078)","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients â‰¥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.","primaryOutcome":{"measure":"Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.","timeFrame":"Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.","effectByArm":[{"arm":"Ibrexafungerp (SCY-078)","deltaMin":142,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":37,"countries":["United States","Austria","Germany","Netherlands","Pakistan","South Africa","Spain","United Kingdom"]},"refs":{"pmids":["31342066"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":102,"n":233},"commonTop":["Diarrhoea","Nausea","Vomiting","Headache","Pyrexia"]}}